Faculty and staff at the Sleep, Mood, Anxiety Research and Treatment Divion (SMART) conduct numerous IRB-approved studies focused on better understanding the development and treatment of sleep and anxiety disorders. If you are interested in participating in or learning more about any of the ongoing studies below please contact Brooke Cameron at camerobr@musc.edu.
Ongoing Studies
Sleep Disorder Study
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated with Shift Work Disorder
- Sponsor: Axsome Therapeutics, Inc.
- Protocol #: SOL-SWD-301
- Study Drug: Solriamfetol
Insomnia Study
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants with Opioid Use Disorder
- NIDA/Merck Sharp & Dohme LLC
- Protocol #: MK-4305
- Study Drug: Suvorexant
Idiopathic Hypersomnia (IH) Study
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
- Sponsor: Harmony Biosciences Management, Inc
- Protocol #: HBS-301-CL-301
- Study Drug: HBS-301 pitolisant
Narcolepsy Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-Label Extension
- Sponsor: Harmony Biosciences Management, Inc
- Protocol #: HBS-301-CL-302
- Study Drug: HBS-301 pitolisant
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
- Sponsor: Eisai Inc.
- Protocol #: E2086-G000-202
- Study Drug: E2086 (novel orexin receptor-2 agonist)
Narcolepsy Type 1 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
- Sponsor: Alkermes, Inc.
- Protocol #: ALKS 2680-302
- Study Drug: ALKS 2680 alixorexton
Narcolepsy Type 2 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
- Sponsor: Alkermes, Inc.
- Protocol #: ALKS 2680-303
- Study Drug: ALKS 2680 alixorexton
